Compound Detail
CHEMBL779
TADALAFIL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
Basic Information
| ChEMBL ID | CHEMBL779 |
| Name | TADALAFIL |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WOXKDUGGOYFFRN-IIBYNOLFSA-N |
| Therapeutic | ✓ Yes |
23
Targets
93
Activities
4
Assay Types
11
PK Parameters
20
Publications
19
Known Names
20
Indications
1
Mechanisms
Molecular Properties
389.4
MW (Da)
2.21
ALogP
4
HBA
1
HBD
74.9
PSA (Ų)
0.69
QED
0
Ro5 Violations
1
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2002 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Phosphodiesterase 5A inhibitor | INHIBITOR | cGMP-specific 3',5'-cyclic phosphodiesterase | ✓ | ✓ |
Indications
Erectile Dysfunction Erectile Dysfunction Hypertension, Pulmonary Hypertension, Pulmonary Prostatic Hyperplasia Pulmonary Arterial Hypertension Glucose Intolerance Heart Defects, Congenital Insulin Resistance Lung Diseases, Interstitial Muscular Dystrophy, Duchenne Premature Ejaculation Raynaud Disease Transposition of Great Vessels Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Cushing Syndrome Dementia, Vascular Diabetes Mellitus, Type 2 Eisenmenger Complex
ATC Classification
G04BE08
tadalafil
Level 1: GENITO URINARY SYSTEM AND SEX HORMONES
Level 2: UROLOGICALS
Activity Summary
IC50 79 meas. best 9.08
EC50 7 meas. best 7.11
Ki 4 meas. best 8.92
Kd 3 meas. best 8.72
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| ADMET CHEMBL612558 | IC50 | 9.08 | 9.08 | 0.8 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | IC50 | 8.92 | 8.2426 | 1.2 | 19 |
| Unchecked CHEMBL612545 | Ki | 8.92 | 8.92 | 1.2 | 1 |
| Unchecked CHEMBL612545 | IC50 | 8.92 | 6.83 | 1.2 | 2 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | Kd | 8.72 | 8.67 | 1.9 | 2 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL3478 | IC50 | 8.48 | 8.2033 | 3.3 | 6 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL4567 | Ki | 8.3 | 8.3 | 5.0 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | Ki | 8.28 | 8.14 | 5.2 | 2 |
| Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A CHEMBL2717 | IC50 | 8.0 | 6.9817 | 10.0 | 12 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL4567 | EC50 | 7.11 | 7.11 | 78.0 | 1 |
| Rattus norvegicus CHEMBL376 | EC50 | 6.82 | 6.56 | 150.0 | 2 |
| Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' CHEMBL3977 | IC50 | 6.4 | 6.4 | 402.0 | 1 |
| Phosphodiesterase 6 CHEMBL2097163 | IC50 | 6.01 | 5.634 | 980.0 | 5 |
| Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha CHEMBL3741 | IC50 | 5.52 | 5.52 | 3000.0 | 1 |
| Nuclear receptor subfamily 2 group E member 1 CHEMBL1961788 | EC50 | 5.3 | 5.3 | 5000.0 | 1 |
| Phosphodiesterase 6 CHEMBL2096979 | IC50 | 5.29 | 5.29 | 5100.0 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | EC50 | 5.24 | 5.24 | 5810.0 | 1 |
| NCI-H1299 CHEMBL612255 | IC50 | 5.11 | 5.09 | 7800.0 | 2 |
| Trypanosoma cruzi CHEMBL368 | IC50 | 5.07 | 5.07 | 8600.0 | 1 |
| Phosphodiesterase 4 CHEMBL2093863 | IC50 | 5.04 | 5.04 | 9200.0 | 1 |
| NCI-H661 CHEMBL1075544 | IC50 | 5.0 | 4.84 | 9900.0 | 2 |
| Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A CHEMBL4295711 | EC50 | 4.96 | 4.81 | 11000.0 | 2 |
| A549 CHEMBL392 | IC50 | 4.91 | 4.5567 | 12200.0 | 3 |
| Acetylcholinesterase CHEMBL3199 | IC50 | 4.58 | 4.58 | 26159.0 | 1 |
| Acetylcholinesterase CHEMBL220 | IC50 | 4.58 | 4.58 | 26100.0 | 1 |
| Leishmania donovani CHEMBL367 | IC50 | 4.4 | 4.4 | 40060.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 4.1 | 4.0333 | 79432.8 | 3 |
| Trypanosoma brucei rhodesiense CHEMBL612348 | IC50 | 4.01 | 4.01 | 97580.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 5.1 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 49.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 5.167 | mL.min-1.kg-1 | Rattus norvegicus |
| F | 63.0 | % | Rattus norvegicus |
| F | 63.0 | % | Rattus norvegicus |
| T1/2 | 2.4 | hr | Rattus norvegicus |
| T1/2 | 17.0 | hr | - |
| T1/2 | 2.4 | hr | Rattus norvegicus |
| T1/2 | 17.5 | hr | Homo sapiens |
| T1/2 | 17.5 | hr | Mus musculus |
| Vd | 5.2 | kg-1 | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine